While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

Share prices of Moderna (NASDAQ: MRNA ... Within respiratory vaccines, the company anticipates FDA approval for an expanded indication of its RSV vaccine. Furthermore, the company has submitted ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

Moderna's strategy in 2025 focuses on maintaining ... Within respiratory vaccines, the company anticipates FDA approval for an expanded indication of its RSV vaccine. Furthermore, the company ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...